Top

Published in:

01-01-2021 | Metastasis | SSAT Plenary Presentation

Alteration of FBXW7 is Associated with Worse Survival in Patients Undergoing Resection of Colorectal Liver Metastases

Authors: Yoshikuni Kawaguchi, Timothy E. Newhook, Hop S. Tran Cao, Ching-Wei D. Tzeng, Yun Shin Chun, Thomas A. Aloia, Arvind Dasari, Scott Kopetz, Jean-Nicolas Vauthey

Published in: Journal of Gastrointestinal Surgery | Issue 1/2021

Abstract

Background

For patients undergoing resection of colorectal liver metastases (CLMs), the prognostic role of somatic gene alterations is increasingly recognized. F-box/WD repeat–containing protein 7 (FBXW7) is a tumor suppressor gene found in approximately 10% of patients with colorectal cancer. The aim of this study is to assess the association of FBXW7 with overall survival after CLM resection.

Methods

Patients who underwent initial CLM resection during 2001–2016 and had genetic sequencing data were studied. Risk factors for overall survival (OS) were evaluated with Cox proportional hazards models using backward elimination.

Results

Of 2045 patients who underwent CLM resection during the study period, 476 were included. The majority (90.5%) underwent prehepatectomy chemotherapy. A total of 27 patients (5.7%) had FBXW7 alteration, along with 240 (50.4%) RAS, 337 (70.8%) TP53, 51 (10.7%) SMAD4, and 27 (5.7%) BRAF. Cox proportional hazards model analyses including 5 somatic gene alteration status and 12 clinicopathologic factors revealed FBXW7(hazard ratio [HR] 1.99, P = 0.015), BRAF (HR 2.47, P = 0.023), RAS (HR 2.42, P < 0.001), TP53 (HR 2.00, P < 0.001), and SMAD4 alterations (HR 1.90, P = 0.004) as significantly associated with OS, together with three clinicopathologic factors, prehepatectomy chemotherapy > 6 cycles (HR 1.51, P = 0.021), number of CLM (HR 1.05, P = 0.007), and largest liver metastasis diameter (HR 1.07, P = 0.023). The covariate-adjusted 5-year OS was significantly lower in patients with FBXW7 alteration than in patients with FBXW7 wild-type (40.4% vs.59.4%, P = 0.015).

Conclusions

FBXW7 alterations are associated with worse survival after CLM resection. The information on multiple somatic gene alterations is imperative for risk stratification and patient selection for CLM resection.

Available only for authorised users

Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Annals of surgery. 1999;230(3):309–18; discussion 18–21.CrossRef

Rees M, Tekkis PP, Welsh FK, O’Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Annals of surgery. 2008;247(1):125-35. https://doi.org/10.1097/SLA.0b013e31815aa2c2.CrossRefPubMed

Nash GM, Gimbel M, Shia J, Nathanson DR, Ndubuisi MI, Zeng ZS et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Annals of surgical oncology. 2010;17(2):572-8. https://doi.org/10.1245/s10434-009-0605-3.CrossRefPubMed

Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, Andreou A et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Annals of surgery. 2013;258(4):619–26; discussion 26–7. https://doi.org/10.1097/SLA.0b013e3182a5025a.CrossRefPubMed

Brudvik KW, Kopetz SE, Li L, Conrad C, Aloia TA, Vauthey JN. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. The British journal of surgery. 2015;102(10):1175-83. https://doi.org/10.1002/bjs.9870.CrossRefPubMed

Amikura K, Akagi K, Ogura T, Takahashi A, Sakamoto H. The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of all-RAS. Journal of surgical oncology. 2018;117(4):745-55. https://doi.org/10.1002/jso.24910.CrossRefPubMed

Wang K, Liu W, Yan XL, Li J, Xing BC. Long-term postoperative survival prediction in patients with colorectal liver metastasis. Oncotarget. 2017;8(45):79927-34. https://doi.org/10.18632/oncotarget.20322.CrossRefPubMedPubMedCentral

Chun YS, Passot G, Yamashita S, Nusrat M, Katsonis P, Loree JM et al. Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases. Annals of surgery. 2019;269(5):917-23. https://doi.org/10.1097/SLA.0000000000002450.CrossRefPubMedPubMedCentral

Kawaguchi Y, Lillemoe HA, Panettieri E, Chun YS, Tzeng CD, Aloia TA et al. Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation. Journal of the American College of Surgeons. 2019;229(3):286-94 e1. https://doi.org/10.1016/j.jamcollsurg.2019.04.027.CrossRefPubMedPubMedCentral

10.

Mizuno T, Cloyd JM, Vicente D, Omichi K, Chun YS, Kopetz SE et al. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2018;44(5):684-92. https://doi.org/10.1016/j.ejso.2018.02.247.CrossRef

11.

Lang H, Baumgart J, Heinrich S, Tripke V, Passalaqua M, Maderer A et al. Extended Molecular Profiling Improves Stratification and Prediction of Survival After Resection of Colorectal Liver Metastases. Annals of surgery. 2019;270(5):799-805. https://doi.org/10.1097/SLA.0000000000003527.CrossRefPubMed

12.

Datta J, Smith JJ, Chatila WK, McAuliffe JC, Kandoth C, Vakiani E et al. Co-Altered Ras/B-raf and TP53 is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Metastatic Colorectal Cancer Patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019. https://doi.org/10.1158/1078-0432.CCR-19-2390.

13.

Gagniere J, Dupre A, Gholami SS, Pezet D, Boerner T, Gonen M et al. Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients. Annals of surgery. 2018. https://doi.org/10.1097/SLA.0000000000002968.

14.

Margonis GA, Buettner S, Andreatos N, Kim Y, Wagner D, Sasaki K et al. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. JAMA surgery. 2018;153(7):e180996. https://doi.org/10.1001/jamasurg.2018.0996.CrossRefPubMedPubMedCentral

15.

Malapelle U, Pisapia P, Sgariglia R, Vigliar E, Biglietto M, Carlomagno C et al. Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. Journal of clinical pathology. 2016;69(9):767-71. https://doi.org/10.1136/jclinpath-2015-203403.CrossRefPubMedPubMedCentral

16.

Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS et al. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget. 2017;8(24):39268-79. https://doi.org/10.18632/oncotarget.16848.CrossRefPubMedPubMedCentral

17.

Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(8):1083-90. https://doi.org/10.1200/JCO.2010.32.6132.CrossRef

18.

Vauthey JN, Chaoui A, Do KA, Bilimoria MM, Fenstermacher MJ, Charnsangavej C et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery. 2000;127(5):512-9. https://doi.org/10.1067/msy.2000.105294.CrossRefPubMed

19.

Kawaguchi Y, Lillemoe HA, Vauthey JN. Dealing with an insufficient future liver remnant: Portal vein embolization and two-stage hepatectomy. Journal of surgical oncology. 2019;119(5):594-603. https://doi.org/10.1002/jso.25430.CrossRefPubMedPubMedCentral

20.

Kawaguchi Y, Kopetz S, Lillemoe HA, Hwang H, Wang X, Tzeng CD, Chun YS, Aloia TA, Vauthey JN. A new surveillance algorithm after resection of colorectal liver metastases based on changes in recurrence risk and ras mutation status. J Natl Compr Canc Netw. 2020;18(11):1500-1508. https://doi.org/10.6004/jnccn.2020.7596.

21.

Kawaguchi Y, Kopetz S, Newhook TE, De Bellis M, Chun YS, Tzeng CD et al. Mutation Status of RAS, TP53, and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019;25(19):5843-51. https://doi.org/10.1158/1078-0432.CCR-19-0863.CrossRef

22.

Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, Handal B et al. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. The Journal of molecular diagnostics : JMD. 2013;15(5):607-22. https://doi.org/10.1016/j.jmoldx.2013.05.003.CrossRefPubMed

23.

Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA: a cancer journal for clinicians. 2017;67(2):93-9. https://doi.org/10.3322/caac.21388.CrossRef

24.

Vauthey JN, Kopetz SE. From multidisciplinary to personalized treatment of colorectal liver metastases: 4 reasons to consider RAS. Cancer. 2013;119(23):4083-5. https://doi.org/10.1002/cncr.28348.CrossRefPubMed

25.

26.

Summers MG, Smith CG, Maughan TS, Kaplan R, Escott-Price V, Cheadle JP. BRAF and NRAS Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017;23(11):2742-9. https://doi.org/10.1158/1078-0432.CCR-16-1541.CrossRef

27.

Schirripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F et al. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. International journal of cancer Journal international du cancer. 2015;136(1):83-90. https://doi.org/10.1002/ijc.28955.CrossRefPubMed

28.

Cercek A, Braghiroli MI, Chou JF, Hechtman JF, Kemeny N, Saltz L et al. Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017;23(16):4753-60. https://doi.org/10.1158/1078-0432.CCR-17-0400.CrossRef

29.

Kawaguchi Y, Lillemoe HA, Vauthey JN. Gene mutation and surgical technique: Suggestion or more? Surgical oncology. 2019. https://doi.org/10.1016/j.suronc.2019.07.004.

30.

Makuch RW. Adjusted survival curve estimation using covariates. Journal of chronic diseases. 1982;35(6):437-43.CrossRef

31.

Ghali WA, Quan H, Brant R, van Melle G, Norris CM, Faris PD et al. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA : the journal of the American Medical Association. 2001;286(12):1494-7.CrossRef

32.

Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018;173(2):321-37 e10. https://doi.org/10.1016/j.cell.2018.03.035.CrossRefPubMedPubMedCentral

33.

Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer research. 2007;67(19):9006-12. https://doi.org/10.1158/0008-5472.CAN-07-1320.CrossRefPubMed

34.

Jardim DL, Wheler JJ, Hess K, Tsimberidou AM, Zinner R, Janku F et al. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PloS one. 2014;9(2):e89388. https://doi.org/10.1371/journal.pone.0089388.CrossRefPubMedPubMedCentral

35.

Lobry C, Oh P, Mansour MR, Look AT, Aifantis I. Notch signaling: switching an oncogene to a tumor suppressor. Blood. 2014;123(16):2451-9. https://doi.org/10.1182/blood-2013-08-355818.CrossRefPubMedPubMedCentral

36.

Masuda K, Ishikawa Y, Onoyama I, Unno M, de Alboran IM, Nakayama KI et al. Complex regulation of cell-cycle inhibitors by Fbxw7 in mouse embryonic fibroblasts. Oncogene. 2010;29(12):1798-809. https://doi.org/10.1038/onc.2009.469.CrossRefPubMed

37.

Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330-7. https://doi.org/10.1038/nature11252.

Title: Alteration of FBXW7 is Associated with Worse Survival in Patients Undergoing Resection of Colorectal Liver Metastases
Authors: Yoshikuni Kawaguchi
Timothy E. Newhook
Hop S. Tran Cao
Ching-Wei D. Tzeng
Yun Shin Chun
Thomas A. Aloia
Arvind Dasari
Scott Kopetz
Jean-Nicolas Vauthey
Publication date: 01-01-2021
Publisher: Springer US
Keywords: Metastasis
Liver Resection
Liver Resection
Colorectal Cancer
Colorectal Cancer
Cytostatic Therapy
Published in: Journal of Gastrointestinal Surgery / Issue 1/2021
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-020-04866-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Alteration of FBXW7 is Associated with Worse Survival in Patients Undergoing Resection of Colorectal Liver Metastases

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Plasma Sodium and Age Are Important Markers of Risk of Perforation in Acute Appendicitis

Development of a Risk Score and Nomogram to Predict Individual Benefit Attained from the Addition of Adjuvant Chemotherapy in the Treatment of Stage II Colon Cancer

Intraductal Oncocytic Papillary Neoplasm of the Pancreas

Contemporary Management of Hepatic Cyst Disease: Techniques and Outcomes at a Tertiary Hepatobiliary Center

Perianal Crohn’s Fistula with Malignant Transformation

A Simple Risk Score to Predict Clavien-Dindo Grade IV and V Complications After Non-elective Cholecystectomy